Anti-CPS1 antibody (ab45956)
Overview
-
Product name
Anti-CPS1 antibody
See all CPS1 primary antibodies -
Description
Rabbit polyclonal to CPS1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Fr, ICC/IF, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat
-
Immunogen
Synthetic peptide corresponding to Human CPS1 aa 800-900 conjugated to keyhole limpet haemocyanin.
(Peptide available asab45955) -
Positive control
- WB: HeLa, A431 and HepG2 whole cell lysates.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituent: PBS
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help. -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab45956 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | Use a concentration of 1 µg/ml. Detects a band of approximately 150 kDa (predicted molecular weight: 140 kDa). | |
| IHC-Fr | Use at an assay dependent concentration. | |
| ICC/IF | Use a concentration of 1 µg/ml. | |
| IHC-P | Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
Function
Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell. -
Tissue specificity
Primarily in the liver and small intestine. -
Involvement in disease
Defects in CPS1 are the cause of carbamoyl phosphate synthetase 1 deficiency (CPS1D) [MIM:237300]. CPS1D is an autosomal recessive disorder of the urea cycle causing hyperammonemia. Clinical features include protein intolerance, intermittent ataxia, seizures, lethargy, developmental delay and mental retardation.
Note=Genetic variations in CPS1 influence the availability of precursors for nitric oxide (NO) synthesis and play a role in clinical situations where endogenous NO production is critically important, such as neonatal pulmonary hypertension, increased pulmonary artery pressure following surgical repair of congenital heart defects or hepatovenocclusive disease following bone marrow transplantation. Infants with neonatal pulmonary hypertension homozygous for Thr-1406 have lower L-arginine concentrations than neonates homozygous for Asn-1406. -
Sequence similarities
Contains 2 ATP-grasp domains.
Contains 1 glutamine amidotransferase type-1 domain. -
Domain
The type-1 glutamine amidotransferase domain is defective. -
Cellular localization
Mitochondrion. - Information by UniProt
-
Database links
- Entrez Gene: 1373 Human
- Entrez Gene: 227231 Mouse
- Entrez Gene: 497840 Rat
- Omim: 608307 Human
- SwissProt: P31327 Human
- SwissProt: Q8C196 Mouse
- SwissProt: P07756 Rat
- Unigene: 149252 Human
see all -
Alternative names
- Carbamoyl phosphate synthase [ammonia] antibody
- Carbamoyl phosphate synthase [ammonia] mitochondrial antibody
- Carbamoyl phosphate synthase antibody
see all
Images
-
Western blot - Anti-CPS1 antibody (ab45956)All lanes : Anti-CPS1 antibody (ab45956) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Performed under reducing conditions.
Predicted band size: 140 kDa
Observed band size: 150 kDa why is the actual band size different from the predicted? -
Immunocytochemistry/ Immunofluorescence - Anti-CPS1 antibody (ab45956)This image is courtesy of an Abreview submitted by Dr Kirk McManusab45956 (1/500) staining CPS1 in HeLa cells (green). Cells were fixed in methanol and counterstained with DAPI in order to highlight the nucleus (red). Please refer to abreview for further experimental details. -
Immunocytochemistry/ Immunofluorescence - Anti-CPS1 antibody (ab45956)ICC/IF image of ab45956 stained human HeLa cells. The cells were PFA fixed (10 min), permabilised in PBS-T (20 min) and incubated with the antibody (ab45956, 1µg/ml) for 1h at room temperature. 1%BSA / 10% normal goat serum / 0.3M glycine was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue). -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPS1 antibody (ab45956)IHC image of CPS1 staining in human liver carcinoma FFPE section, performed on a BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab45956, 1µg/ml, for 8 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. -
Immunohistochemistry (Frozen sections) - Anti-CPS1 antibody (ab45956)This image is courtesy of an anonymous abreview.ab45956 (1/200) staining CPS1 in mouse liver sections (red). Tissue sections were fixed in formaldehyde, blocked and then stained overnight at 4°C. Please refer to abreview for further experimental details.
Protocols
Datasheets and documents
References
ab45956 has been referenced in 8 publications.
- El-Sheikh RM et al. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS 127:93-105 (2019). PubMed: 30698308
- Soria LR et al. Hepatic glutamine synthetase augmentation enhances ammonia detoxification. J Inherit Metab Dis 42:1128-1135 (2019). PubMed: 30724386
- Burke ZD et al. Spatiotemporal regulation of liver development by the Wnt/ß-catenin pathway. Sci Rep 8:2735 (2018). WB . PubMed: 29426940
- Khoja S et al. Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy. Mol Genet Metab N/A:N/A (2018). WB . PubMed: 29801986
- Kang YBA et al. Metabolic Patterning on a Chip: Towards in vitro Liver Zonation of Primary Rat and Human Hepatocytes. Sci Rep 8:8951 (2018). ICC/IF . PubMed: 29895900
- Cüre MC et al. Infliximab Modulates Cisplatin-Induced Hepatotoxicity in Rats. Balkan Med J 33:504-511 (2016). PubMed: 27761277
- Ma SL et al. Co-expression of the carbamoyl-phosphate synthase 1 gene and its long non-coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma. Mol Med Rep 12:7915-26 (2015). WB . PubMed: 26499888
- Cure E et al. Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats. Biomed Res Int 2014:907915 (2014). IHC ; Rat . PubMed: 24551855
